Halozyme posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. The regimen included PEGPH20 and the cancer drug Gemzar. Halozyme said PEGPH20 may make tumors more vulnerable to treatment by depleting their defenses and changing their metabolism.
Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.
Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule.
High-shear mixers that can be quickly and cost-effectively customized to meet unique processing challenges. Mixing processes vary from each application but having a flexible bowl configuration offers greater efficiency and permits working volumes from 30 – 90% of full capacity.
The ChemSeal line features both single and double cartridge configurations designed for easy installation and maintenance. The ChemSeal cartridge seals can be readily removed from the agitator as a complete assembly and quickly repaired on the workbench before re-installation, saving maintenance time and effort.
The 500 Grinder Pumps feature compact, lightweight designs that combine an efficient solids reduction unit with a high performance progressing cavity pump. It offers a variety of innovative design characteristics.
The two one way respiratory valves are made of polypropylene and medical grade silicone featuring molded arrows to indicate the direction of flow. The are designed to allow the flow of gases in only one direction.
The bins are filled, discharged and washed 'off-line' (in parallel) so the blender can be used batch after batch without stopping for product changeover. In addition, loading and unloading of the machine (placing and removal of containers) only takes a few minutes.
This line of dry running and oil-lubricated rotary vane vacuum pumps includes central vacuum systems that have had a positive impact on the pharmaceutical industry. The pumps are geared towards mixing, blending and drying machines that manufacture various types of pharmaceutical products.
Cancer cells typically put up a chemical shield to protect against the body's disease-fighting T-cells. But innunotherapy can break through the shiled and let the T-Cells get to work. Yervoy is one of the newest immunotherapy drugs and In early cases has show remarkable results.
Scientists have finally recovered stem cells from cloned human embryos, a longstanding goal that could lead to new treatments for such illnesses as Parkinson's disease and diabetes. A prominent expert called the work a landmark, but noted that a different, simpler technique now under development may prove more useful.
Prestige Brands Holdings Inc. returned to a profit in its fiscal fourth quarter, benefiting from lower operating expenses and better sales of over-the-counter health care products. The company, which distributes over-the-counter and household cleaning products like Clear Eyes and PediaCare, reported net income of $19.3 million, or 37 cents per share, for the three months ended March 31.
The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones. The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone.
In the new psychiatric manual of mental disorders, grief soon after a loved one's death can be considered major depression. Extreme childhood temper tantrums get a fancy name. And certain "senior moments" are called "mild neurocognitive disorder."
Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.